Last reviewed · How we verify

Ropivacaine + Midazolam

Aga Khan University · FDA-approved active Small molecule

Ropivacaine blocks sodium channels to provide local anesthesia, while midazolam enhances sedation and anxiolysis through GABAergic receptor modulation.

Ropivacaine blocks sodium channels to provide local anesthesia, while midazolam enhances sedation and anxiolysis through GABAergic receptor modulation. Used for Local anesthesia with sedation for surgical and diagnostic procedures, Regional anesthesia with anxiolysis.

At a glance

Generic nameRopivacaine + Midazolam
SponsorAga Khan University
Drug classLocal anesthetic + benzodiazepine combination
TargetVoltage-gated sodium channels (ropivacaine); GABA-A receptors (midazolam)
ModalitySmall molecule
Therapeutic areaAnesthesia/Pain Management
PhaseFDA-approved

Mechanism of action

Ropivacaine is a long-acting amide local anesthetic that reversibly inhibits sodium influx in nerve fibers, preventing depolarization and conduction of action potentials. Midazolam is a benzodiazepine that potentiates inhibitory GABA signaling in the central nervous system, producing sedation, anxiolysis, and amnesia. Together, this combination provides both local pain control and systemic sedation for procedures.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: